Skip to content

Home
Immuno-Oncology
Therapies
- Approved Drugs
- Experimental Therapies
  - a
    - Actimmune
    - ABBV-181
    - ABBV-428
    - ABP798
    - Adagloxad Simolenin
    - ADU-741 (JNJ-64041809 )
    - ADXS-HER2
    - ADXS-PSA
    - AE37
    - AFM11
    - AFM13
    - AGEN1884
    - AGEN2034
    - ALKS 4230
    - AlloStim
    - AM0010 (Pegilodecakin)
    - AMG 211 (MEDI-565)
    - AMG 330
    - AMG 420
    - APVO414 (MOR209/ES414)
    - AST-VAC1
    - ATA520
    - AutoSynVax
  - b-c
  - D-F
  - G-I
    - GALE-301
    - Galinpepimut-S
    - Ganitumab
    - GBR 1342
    - GI-6207
    - GI-6301
    - GL-ONC1
    - Gliovac (ERC1671)
    - GP2
    - GRN-1201
    - GSK3174998
    - GWN323
    - HF10
    - ICT-107
    - ICT-121
    - IGN002
    - IMCgp100
    - IMP701
    - INCAGN1949
    - INO-1400
    - INO-3106
    - INO-5150
    - INO-9012
  - J-L
  - M-O
    - M7824
    - MAGE-A10 T-Cell Therapy
    - MBG453
    - MDNA55
    - MEDI0457
    - MEDI0562
    - MEDI0680
    - MGA012
    - MGD009
    - MK-4166
    - Mogamulizumab
    - MVA-BN Brachyury
    - MVI-118
    - NEO-PV-01
    - NeuVax (Nelipepimut-S)
    - NKR-2
    - NKTR-214
    - NY-ESO TCR
    - Opdivo (Nivolumab)
    - OncoVAX
    - ONCOS-102
  - P-S
    - PAN-301-1
    - PDR001
    - PDS0101
    - PF-04518600
    - PF-06801591
    - PNK-007
    - ProscaVax
    - PVRIG
    - Provenge (Sipuleucel-T)
    - REGN2810 (SAR439684)
    - REGN3767
    - Relatlimab
    - Reolysin
    - RG7802
    - RG7828
    - Rocapuldencel-T
    - rSIFN-co
    - SHR-1210
    - SL-701
    - SurVaxM
  - T-Z
    - TT12
    - Tedopi (OSE-2101)
    - Telomelysin (OBP-301)
    - TG4010
    - TPIV 200
    - TPIV200
    - Traumakine
    - TRX518
    - TSR-022
    - TSR-042
    - Utomilumab
    - ValloVax
    - Varlilumab
    - Vigil
    - Viagenpumatucel-L
    - VX15
    - VBI-1901
    - XmAb13676
    - VGX-3100
    - Yervoy (Ipilimumab)
Categories
Subscribe
Login

Search for:

Register

Home » Register

Start a subscription

Please go to the subscribe page to choose a subscription level.

Subscription Support

Search for:

Create your own user feedback survey

Recent Posts

Treatment With VBI-1901 Linked to Tumor Stabilization in Recurrent Gliobastoma Patients in Phase 1/2 Trial

November 15, 2019
CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma

November 13, 2019
2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

November 11, 2019
MDNA55 Increases Survival in Glioblastoma, Notably in Patients With High ILR4 Levels, Early Trial Data Show

November 8, 2019

Featured Posts

First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors

May 17, 2019

PureTech Presents Data About Two Promising Anti-cancer Therapies

April 26, 2019

Combining Radiation with Immune Checkpoint Inhibitors Improved Outcomes in Glioblastoma Mice

May 7, 2019

Visit Immuno-Oncology News's profile on Pinterest.

Immuno-Oncology News

BioNews Services, LLC

1601 Market St.
Suite 20B103
Philadelphia, PA 19103
Email: [email protected]
Phone: 1-800-936-1363

About Immuno-Oncology News
Our Team
Our Guiding Ethics
Keytruda (Pembrolizumab)
Contact Us
Privacy Policy
Terms of Service
Disable Notifications

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2019 All rights reserved.

Pin It on Pinterest

Share This

Facebook
Twitter
Google+
Pinterest
LinkedIn

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. Ok Read more